Cantor Fitzgerald Comments on Korro Bio FY2025 Earnings

Korro Bio, Inc. (NASDAQ:KRRO) – Analysts at Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for Korro Bio in a research report issued on Thursday, May 8th. Cantor Fitzgerald analyst S. Seedhouse now anticipates that the company will post earnings per share of ($8.76) for the year, up from their prior estimate of ($8.91). Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for Korro Bio’s current full-year earnings is ($9.52) per share.

Several other analysts have also recently weighed in on KRRO. HC Wainwright dropped their price objective on shares of Korro Bio from $115.00 to $100.00 and set a “buy” rating for the company in a research note on Thursday, May 8th. Royal Bank of Canada lowered their target price on shares of Korro Bio from $105.00 to $95.00 and set an “outperform” rating on the stock in a report on Wednesday, March 19th. Oppenheimer cut their price target on Korro Bio from $155.00 to $90.00 and set an “outperform” rating for the company in a research note on Tuesday. Finally, Chardan Capital reissued a “buy” rating and set a $25.00 price target on shares of Korro Bio in a research report on Tuesday. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $104.63.

Korro Bio Stock Performance

Shares of Korro Bio stock opened at $15.55 on Monday. The firm has a 50-day moving average of $17.53 and a 200-day moving average of $33.59. Korro Bio has a 52-week low of $11.13 and a 52-week high of $98.00. The stock has a market cap of $146.03 million, a PE ratio of -1.65 and a beta of 2.66.

Korro Bio (NASDAQ:KRRO) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($2.49) EPS for the quarter, beating analysts’ consensus estimates of ($2.60) by $0.11. The firm had revenue of $2.55 million during the quarter, compared to analyst estimates of $0.13 million.

Hedge Funds Weigh In On Korro Bio

Hedge funds and other institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. boosted its position in shares of Korro Bio by 374.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 12,391 shares of the company’s stock worth $414,000 after acquiring an additional 9,782 shares in the last quarter. Rhumbline Advisers lifted its stake in Korro Bio by 7.8% during the fourth quarter. Rhumbline Advisers now owns 9,602 shares of the company’s stock worth $366,000 after purchasing an additional 691 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Korro Bio by 3.0% in the 4th quarter. Bank of New York Mellon Corp now owns 14,788 shares of the company’s stock valued at $563,000 after purchasing an additional 435 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Korro Bio in the 4th quarter valued at $394,000. Finally, AlphaQuest LLC increased its stake in shares of Korro Bio by 23.2% in the 4th quarter. AlphaQuest LLC now owns 2,189 shares of the company’s stock valued at $83,000 after purchasing an additional 412 shares during the last quarter. 13.18% of the stock is currently owned by institutional investors and hedge funds.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).